Results 31 to 40 of about 6,967 (165)
Pharmacotherapy for Cirrhosis in Japan
Portal Hypertension &Cirrhosis, EarlyView.As cirrhosis progresses from the compensated to the decompensated stage, liver disease‐related events such as varices, ascites, encephalopathy, sarcopenia, jaundice, and bleeding tendency, as well as liver carcinogenesis, can occur at a high rate. With the advent of new pharmacotherapies for cirrhosis in the last decade, liver fibrosis has been shown ...
Hiroki Nishikawa, Soo Ki Kim, Akira Asai
wiley +1 more source
British Journal of Clinical Pharmacology, Volume 91, Issue 4, Page 1132-1156, April 2025.Abstract Structured medication reviews (SMRs) were introduced into the National Health Service (NHS) Primary Care to support the delivery of the NHS Long‐Term Plan for medicines optimization. SMRs improve the quality of care, reduce harm and offer value for money. However, evidence to support SMRs for patients with chronic kidney disease (CKD) stage G4‐
Cathy Margaret Pogson +3 more
wiley +1 more source
PHS48 Cost-Effectiveness Analysis of Tolvaptan for Hyponatreamia in South Korea [PDF]
, 2005 Lanz, AlfredoPla general de la part frontal de dona ajaguda sobre un suport en forma de llit o taula. Va ser donada per l'autor, Alfredo Lanz, i simbolitza el mar Mediterrani.
Kang, H.J. +3 more
core +1 more source
Management of Cirrhotic Ascites under the Add-on Administration of Tolvaptan [PDF]
, 2021 Tolvaptan is a recently available diuretic that blocks arginine vasopressin receptor 2 in the renal collecting duct. Its diuretic mechanism involves selective water reabsorption by affecting the water reabsorption receptor aquaporin 2.
Adachi, Takuya +7 more
core +1 more source
Diabetes, Obesity and Metabolism, EarlyView.Abstract Albuminuria, the abnormal presence of albumin in urine, is a key marker of kidney damage and a strong predictor of kidney and cardiovascular outcomes. Its clinical significance has evolved from early historical observations to its current role in chronic kidney disease (CKD) detection, risk stratification and treatment monitoring.
Jelle M. Beernink +4 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 3, Page 1965-1976, June 2025.Abstract Background The optimal strategy for modern chemotherapy should be based on a comprehensive approach for cancer patients with cardiovascular diseases. Therefore, cardio‐oncology has received increasing attention owing to the cardiotoxic effects of anti‐cancer therapies.
Tomiko Sunaga +7 more
wiley +1 more source
Synthesis and Characterization of Tolvaptan Impurities [PDF]
Advances in Chemistry, 2014 Twenty-six possible as well as observed impurities during the preparation of Tolvaptan have been identified, prepared, and characterized by HPLC (high performance liquid chromatography), NMR (nuclear magnetic resonance), and mass spectra. Control of these impurities, formed during various stages of Tolvaptan preparation, has been mentioned in this ...
Rajakrishna Yerramalla +4 more
openaire +2 more sources
ESC Heart Failure, Volume 12, Issue 3, Page 2023-2033, June 2025.Abstract Aims Dapagliflozin (DAPA), a sodium‐glucose co‐transporter 2 inhibitor, has been shown to reduce cardiovascular mortality among patients with chronic heart failure. We aimed to evaluate the impact on a worsening renal function (WRF) by adding DAPA as compared to standard decongestive therapy with loop diuretics alone.
Shodai Kawanami +11 more
wiley +1 more source
Clinical effect of long-term administration of tolvaptan in patients with heart failure and chronic kidney disease [PDF]
, 2019 学位記番号 ...
Ono, Yohei +2 more
core
Tolvaptan as a tool in renal physiology
American Journal of Physiology-Renal Physiology, 2014 For decades, the Brattleboro rat has been a useful model in kidney physiology. These animals manifest central diabetes insipidus (lack of circulating vasopressin) due to a mutation in the vasopressin-neurophysin gene. V2 receptor-mediated vasopressin actions in the kidney can be assessed in these animals by infusing the V2-selective vasopressin analog ...
Chung-Lin Chou +3 more
openaire +4 more sources